00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Novo Nordisk CEO Mike Dustar said the company's obesity medicines may have uses beyond weight loss.
00:10Speaking Sunday at the American Diabetes Association conference in New Orleans,
00:14Dustar said Novo is exploring whether future generations of GLP-1 medicines
00:19could treat additional diseases beyond obesity and diabetes.
00:23Researchers at the conference presented data suggesting semaglutide
00:27reduced the biological age of the heart and kidneys based on experimental measurements,
00:32though the analysis did not prove the drug slows aging.
00:36Dustar also said Novo is considering appearance-related treatments such as skin care and hair loss.
00:41The pharma giant reported positive phase 3 trial results in April
00:45for oral semaglutide in children and adolescents with type 2 diabetes,
00:49showing reductions in blood sugar levels.
00:51Shares were down by 1.05% at $42.51 in Monday's pre-market trading,
00:57according to data from Benzinga Pro.
00:58For all things money, visit Benzinga.com.
Comments